Drug Profile
EL 530
Alternative Names: NaPa; Phenylacetic-acidLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Uniformed Services University of the Health Sciences
- Class Esters; Phenylacetates; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Hyperammonaemia
- Discontinued Prostate cancer
Most Recent Events
- 18 Dec 2013 Elan Corporation has been acquired and merged into Perrigo
- 25 Aug 1998 Targon no longer holds development rights to EL 530
- 23 Feb 1998 Launched for Hyperammonaemia in USA (IV)